GenSight Biologics (GSGTF), a biopharma company focused on gene therapies for retinal neurodegenerative diseases and central nervous ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...

Today's Amazon 'Deals of the Day' also include the Amazon Fire HD 10 Kids Pro tablet for over 25% off and the TP-Link Archer ...

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports ...

Higher consumption of green tea, but not coffee, was associated with fewer cerebral white matter lesions in prospective ...

New York Governor Kathy Hochul signed into law two bills (A8872A and S2376B; collectively, the “Bills”) that amend New York’s ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic retinopathy, diabetic macular edema and age-related macular degeneration. The ...

Background Small hard macular drusen can be observed in the retina of adults as young as 18 years of age. Here, we seek to describe the in vivo topography and geometry of these drusen. Methods Retinal ...